Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Firs...
January 28 2016 - 8:00AM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that it plans to report its financial results for its
fiscal first quarter ended December 31, 2015 after the U.S. markets
close on February 8, 2016. Enanta management will host a conference
call at 4:30 p.m. ET to discuss these results and provide an update
on Enanta’s research and development pipeline.
Conference Call and Webcast InformationTo participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the
conference call will be available starting at approximately 7:30
p.m. Eastern time on February 8, 2016, through 11:59 p.m. Eastern
time on February 12, 2016 by dialing (855) 859-2056 from the U.S.
or (404) 537-3406 for international callers. The passcode for both
the live call and the replay is 36743436. A live audio webcast of
the call and replay can be accessed by visiting the “Calendar of
Events” section on the “Investors” page of Enanta’s website at
www.enanta.com.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta’s research and development is currently focused on four
disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV),
Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial
Virus (RSV). Enanta has developed novel protease inhibitors and
NS5A inhibitors that are members of the direct-acting-antiviral
(DAA) inhibitor classes designed for use against the hepatitis C
virus (HCV). Enanta’s protease inhibitors, developed through its
collaboration with AbbVie, include paritaprevir, which is contained
in AbbVie’s marketed DAA regimens for HCV, and ABT-493, Enanta’s
next-generation protease inhibitor, which AbbVie is developing in
phase 3 studies in combination with ABT-530, AbbVie’s
next-generation NS5A inhibitor. Enanta has also discovered a
cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism
for HCV, which is now in a phase 1 clinical development, and
EDP-305, an FXR agonist, which Enanta plans to advance into
clinical development for NASH later in 2016. Please visit
www.enanta.com for more information on our programs and
pipeline.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160128005123/en/
Investor Contact:Enanta Pharmaceuticals, Inc.Carol
Miceli, 617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024